Welcome to our dedicated page for DAMORA THERAPEUT news (Ticker: DMRA), a resource for investors and traders seeking the latest updates and insights on DAMORA THERAPEUT stock.
Damora Therapeutics, Inc. reports news around its biotechnology pipeline for mutCALR-driven blood disorders, financial results, and corporate development following the completed acquisition that added DMR-001, DMR-002, and DMR-003. Company updates also describe governance changes, board and executive appointments, and equity compensation actions under Nasdaq inducement-grant rules.
Recurring Damora news centers on hematologic disorders, myeloproliferative neoplasms, research and development progress, capital resources, and public-company governance matters tied to its Nasdaq-listed common stock.
Damora Therapeutics (NASDAQ: DMRA) reported full-year 2025 results and corporate milestones on March 19, 2026. The company completed acquisition of mutCALR-focused assets, raised gross proceeds of approximately $285 million (private) and $316 million (public), and holds about $535 million in cash as of February 28, 2026. Damora expects an IND/CTA for lead candidate DMR-001 by mid-2026 and two proof-of-concept datasets beginning mid-2027.
2025 results include R&D expense of $26.9M, G&A of $9.7M, and a net loss of $209.8M largely driven by a $174.3M acquired in-process R&D charge.